Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Updates on trial and patient experience with artificial cornea ➤ Positive clinical trial update for Usher syndrome type 1B ➤ Positive topline data from Phase 2 study investigating DME and nAMD treatment ➤ First patient dosed in second Phase 3 trial evaluating drop for night vision disturbances ➤ Partnership and company news ➤ ASCRS news and events
➤ New designations granted to investigational treatment for retinal dystrophies ➤ Status update on BLA for bevacizumab for treatment of retinal diseases ➤ Acquisition news ➤ ASCRS news and events
➤ Accommodating lens implanted in first patient ➤ First patient dosed in Phase 2 trial investigating treatment for normal tension glaucoma ➤ Primary endpoint met in Phase 3 trial for glaucoma drop ➤ CE mark approvals ➤ Regenerative Medicine Advanced Therapy designation granted to investigational gene therapy for Stargardt disease ➤ ASCRS news and events
➤ Phase 2 trial is the ‘first and only’ to show vision improvement for Stargardt disease ➤ IND accepted for retinal disease gene therapy and Phase 1/2 trial to begin ➤ First patients dosed in trial evaluating retinitis pigmentosa treatment ➤ LASIK alternative being researched ➤ Partnership news ➤ ASCRS news and events
➤ First gene therapy treatment for macular telangiectasia type 2 performed outside of trial ➤ First patient enrolled in Phase 2b study of ocular micro implant for IOP reduction ➤ Fast Track Designation granted to Stargardt gene therapy ➤ FDA Special Protocol Assessment for non-proliferative diabetic retinopathy trial ➤ IDE granted to new glaucoma therapy system ➤ Partnership news ➤ ASCRS news and events
➤ FDA approves aceclidine-based drop for presbyopia ➤ Long-term data supports efficacy of continuous wet AMD treatment ➤ First patient dosed in trial for drug eluting lacrimal canaliculus plug ➤ Acquisition news ➤ ASCRS news and events
➤ Phase 3 results for preservative-free redness reliever ➤ Enrollment complete in Phase 3 pivotal program for wet AMD treatment ➤ Dry AMD Phase 3 trial completes enrollment ➤ Study: 24-month data confirm durability of dry eye procedural treatment ➤ Partnership and acquisition news ➤ ASCRS news and events
➤ Topline Phase 2 results for drug treating neuropathic corneal pain ➤ Phase 3 blepharitis treatment doesn’t meet primary endpoint ➤ Study: therapeutic potential of collagen mimetic peptides for myopia ➤ FDA accepts NDA resubmission for dry eye therapy ➤ Partnership news ➤ ASCRS news and events
➤ Fast Track designation granted to one-time intravitreal gene therapy for geographic atrophy ➤ FDA clears IND for Stargardt gene therapy to move forward into a Phase 1/2 clinical trial ➤ BLA submission for retinitis pigmentosa gene therapy begins ➤ First patient dosed in Phase 1/2 trial evaluating NK therapy ➤ Enrollment complete in Phase 2b trial for PCED therapy ➤ ASCRS news and events
➤ Results from second Phase 3 pivotal trial for presbyopia drop ➤ Interim Phase 2 data presented on DME, wet AMD treatment ➤ Phase 2 trial to investigate oral DME treatment ➤ First patient dosed in investigational cell therapy for photoreceptor diseases ➤ Phase 1 trial begins for minimally invasive dry AMD treatment ➤ Acquisitions and other company news ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.